文献速递介入腹部USCTDSA

博来霉素联合碘化油经皮硬化治疗症状性巨大肝血管瘤的前瞻性研究

Percutaneous Sclerotherapy with Bleomycin and Ethiodized Oil: A Promising Treatment in Symptomatic Giant Liver Hemangioma.
PubMed 文献 · Radiology · 2021-08-17

单中心前瞻性研究纳入28例症状性巨大肝血管瘤患者,行超声和透视引导下博来霉素联合碘化油经皮硬化治疗,技术成功率100%,12个月随访VAS评分降低83.5%、瘤体体积缩小76%,无主要并发症,提示该方法安全可行且疗效显著。

要点

  • 博来霉素联合碘化油经皮硬化治疗症状性巨大肝血管瘤技术成功率100%,可显著缓解腹痛或腹胀。
  • 12个月随访VAS评分平均降低83.5%,瘤体体积平均缩小76%,61%患者症状完全缓解。
  • 无主要并发症,提示该治疗方式安全性良好,可作为症状性巨大肝血管瘤的候选治疗。

核心结论

  • 经皮硬化治疗对症状性巨大肝血管瘤患者安全、可行,初步结果良好。

研究设计与样本

  • 单中心前瞻性研究,2018年9月至2020年7月纳入28例有腹部疼痛或腹胀的症状性巨大肝血管瘤患者(平均年龄45岁±9,25例女性)。
  • 在超声和透视引导下,使用博来霉素与碘化油混合液行经皮硬化治疗,记录技术成功率。
  • 主要结局为视觉模拟量表(VAS)症状严重程度变化,次要结局为基于CT的病灶体积变化及介入放射学会分类的并发症,术后6和12个月记录。
  • 采用Wilcoxon符号秩检验或配对t检验进行比较。

诊断标准与关键数值

  • 技术成功率为100%。
  • 平均VAS评分从术前8.3降至6个月随访1.4(降低84.7%)和12个月随访1.5(降低83.5%),P均<.001。
  • 12个月随访时所有患者症状缓解,其中17/28(61%)完全缓解,11/28(39%)部分缓解。
  • 平均巨大肝血管瘤体积从856.3 cm3降至6个月309.8 cm3(缩小65.7%)和12个月206.0 cm3(缩小76%),P均<.001。
  • 未检测到主要并发症。

临床应用与阅片要点

  • 对于有症状的巨大肝血管瘤,可考虑在超声和透视引导下行博来霉素联合碘化油经皮硬化治疗。
  • 术后应随访VAS评分和CT体积变化以评估疗效,注意观察有无并发症。
  • 该治疗技术成功率高,但需注意本研究的单中心设计和样本量有限,推广需谨慎。

局限性

  • 单中心研究,样本量较小(28例),结果外推需谨慎。
  • 随访时间较短(12个月),长期疗效和安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Percutaneous sclerotherapy with bleomycin has been proven to have a potential benefit in the management of low-flow venous malformations. Liver hemangiomas are considered low-flow venous malformations. Thus, percutaneous sclerotherapy could potentially have a promising result in their management. Purpose To investigate the feasibility, efficacy, and safety of percutaneous sclerotherapy with bleomycin in the management of symptomatic giant liver hemangioma (GLH). Materials and Methods This single-institute prospective study was conducted between September 2018 and July 2020. Percutaneous sclerotherapy was performed using a mixture of bleomycin and ethiodized oil under guidance of US and fluoroscopy in participants with GLH who were experiencing related abdominal pain or fullness. Technical success was recorded. Change in symptom severity, according to visual analog scale (VAS), was considered the primary outcome of the study. Volume change, based on the lesion volume at CT, and complications, based on the classification of the Society of Interventional Radiology, were regarded as secondary outcomes. The primary and secondary outcomes were recorded 6 and 12 months after the procedure. Comparison was performed by using the Wilcoxon signed-rank test or paired t test. Results Twenty-eight participants (mean age, 45 years ± 9; 25 women) were evaluated. Technical success was 100%. The mean VAS score was 8.3 before the procedure, which decreased to 1.4 (84.7% reduction) and 1.5 (83.5% reduction) at 6- and 12-month follow-ups, respectively (P < .001 for both). All participants reported relief of symptoms (17 of 28 participants [61%] with complete relief; 11 [39%] with partial relief) at 12-month follow-up. Mean GLH volumes dropped from 856.3 cm3 to 309.8 cm3 (65.7% reduction) and 206.0 cm3 (76% reduction) at 6- and 12-month follow-ups, respectively (P < .001 for both). No major complications were detected. Conclusion Percutaneous sclerotherapy is a safe and feasible method with promising results in the treatment of patients with symptomatic giant liver hemangioma. Clinical trial registration no. NCT03649113 © RSNA, 2021 See also the editorial by McGahan and Goldman in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ayoobi Yazdi N, Mehrabinejad MM, Dashti H, et al. Percutaneous Sclerotherapy with Bleomycin and Ethiodized Oil: A Promising Treatment in Symptomatic Giant Liver Hemangioma. Radiology. 2021. PMID: 34402664. doi:10.1148/radiol.2021204444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。